This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Endo Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Endo Pharmaceuticals Holdings Inc. ( ENDP)

Q4 2011 Earnings Call

February 24, 2012 8:30 am ET

Executives

David Holveck – President, Chief Executive Officer

Alan Levin – Executive Vice President, Chief Financial Officer

Julie McHugh – Chief Operating Officer

Dr. Ivan Gergel – Chief Scientific Officer

Blaine Davis – Vice President, Corporate Affairs

Analysts

Gregg Gilbert – Bank of America Merrill Lynch

John Boris – Citigroup

Shibani Malhotra – RBC Capital Markets

Corey Davis – Jefferies

David Ansellem – Piper Jaffray

Ken Cacciatore – Cowen & Co.

Chris Schott – JP Morgan

Annabel Samimy – Stifel Nicolaus

Jim Dawson – Buckingham Research

Michael Tong – Wells Fargo

Gary Nachman – Susquehanna Financial Group

Presentation

Operator

Good day ladies and gentlemen and welcome to the Fourth Quarter 2011 Endo Pharmaceuticals Holdings Inc. Earnings conference call. My name is Lacey and I’ll be your coordinator for today. At this time, all participants are in listen-only mode. We will facilitate a question and answer session towards the end of the presentation. If at any time during the call you require assistance, please press star followed by zero and a coordinator will be happy to assist you. As a reminder, this conference is being recorded for replay purposes.

I would now like to turn the presentation over to your host for today’s call, Mr. Blaine Davis, Vice President of Corporate Affairs. Please proceed.

Blaine Davis

Great, thanks Lacey. Good morning everybody and thank you for joining us. With me on this morning’s call are Dave Holveck, President and CEO of Endo; Julie McHugh, Chief Operating Officer; Dr. Ivan Gergel, Chief Scientific Officer, and Alan Levin, Chief Financial Officer. After our prepared remarks, we’ll open the call to your questions.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,776.91 +93.33 0.53%
S&P 500 2,081.34 +12.58 0.61%
NASDAQ 4,997.4590 +5.5190 0.11%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs